62/100BBeiGene company profile
- CEO
- John V. Oyler
- Employees
- 12,000
- Headquarters
- Aeschengraben 27, Basel, PA 4051, CH
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO date
- 3 Feb 2016
- Stock exchange
- NASDAQ
- ISIN
- US07725L1026
Website:beonemedicines.com
About the company
BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company’s commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; SYLVANT for the treatment of adult patients with multicentric castleman disease; BAITUOWEI for patients with BC in premenopausal and perimenopausal women, and cancer; and PARTRUVIX for the treatment of various solid tumors. Its clinical stage products comprise Sonrotoclax BGB-11417, a small molecule Bcl-2 inhibitor; BGB-16673, a BTK targeting chimeric degradation activation compound active against wild type and mutant BTK; BG-60366, an EGFR-targeted CDAC; BG-89894 (SYH2039), a MAT2A Inhibitor; BGB-58067, an MTA-Cooperative PRMT5 Inhibitor; BG-T187 and BG-C0902, an anti-EGFRxMET trispecific antibody; BGB-26808, a HPK-1 Inhibitor; BGB-C354, an anti-B7H3 ADC; Zanidatamab, a bispecific HER2-targeted antibody; BG-C137, an anti-FGFR2b ADC; BGB-53038, a Pan-KRAS Inhibitor; BGB-B2033, an anti-GPC3x4-1BB bispecific antibody; BGB-B3227, an anti-MUC1xCD16A bispecific antibody; BG-C477, an anti-CEAADC; BGB-43395, a CDK4 Inhibitor; BG-68501, a CDK2 Inhibitor; BG-C9074, an anti-B7H4 ADC; BGB-21447, a Bcl-2 Inhibitor; and BGB-45035, an IRAK4-targeted CDAC. It also has various preclinical programs. The company has agreements Amgen, BMS, Bio-Thera, EUSA Pharma, Luye Pharmaceutical, and Novartis. The company was formerly known as BeiGene, Ltd. and changed its name to BeOne Medicines AG in May 2025. BeOne Medicines AG was founded in 2010 and is based in Basel, Switzerland.
Employees
BeiGene had about 12,000 employees at the end of fiscal year 2025 (31 December 2025), by its annual report. That is 9.1% more than a year before.
Employees at each fiscal year end, as the company reports them in its annual report (10-K); revenue and net income per employee are the fiscal year's over that count.
Who owns BeiGene
Institutions such as funds, banks and insurers held 31.3% of BeiGene's shares on 30 June 2026, 297 of them reporting holdings to the SEC; the rest is held by individual investors and other shareholders.
Shares free to trade
Closely held shares belong to insiders, founders and owners of more than 5%, and seldom change hands. The free float is the rest: the shares anyone can buy and sell.
How BeiGene pays its executives
| Name and position | Salary | Stock awards | Option awards | Cash incentive | Other pay | Total pay |
|---|---|---|---|---|---|---|
| Chan Lee, Senior Vice President, General Counsel and Corporate Secretary | 659.49K USD | 15.25M USD | 1.75M USD | 585.63K USD | 74.70K USD | 18.32M USD |
| Aaron Rosenberg, Chief Financial Officer | 1.13M USD | 11.25M USD | 3.75M USD | 1.68M USD | 133.83K USD | 17.94M USD |
| Dr. Lai Wang, President, Global Head of Research and Development | 862.41K USD | 7.50M USD | 2.50M USD | 957.28K USD | 210.00K USD | 12.03M USD |
| Dr. Xiaobin Wu, President and Chief Operating Officer | 660.00K USD | 3.87M USD | 1.29M USD | 586.08K USD | 21.00K USD | 6.43M USD |
FY2025 · From the company's proxy statements to the SEC: what each named executive was paid for the fiscal year, shares and options at their value when granted. The latest filing
Common questions about BeiGene
Source: Financial Modeling Prep